Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19642537 | 0.94 | KMO (0.55) | KMOPPARGPPARAFFAR1 | |
| SCHEMBL3973133 | 0.89 | GSK3B (0.55) | PTPN1GSK3B | |
| SCHEMBL29499477 | 0.89 | GSK3B (0.55) | PTPN1GSK3B | |
| SCHEMBL19642672 | 0.79 | KMO (0.75) | KMO | |
| SCHEMBL19660153 | 0.78 | L3MBTL1 (0.43) | KMOFFAR1 | |
| SCHEMBL29391582 | 0.76 | GSK3B (0.60) | PTPN1GSK3B | |
| SCHEMBL311275 | 0.76 | GSK3B (0.60) | PTPN1GSK3B | |
| SCHEMBL6559766 | 0.76 | KCNQ3 (0.47) | KMO | |
| SCHEMBL30467135 | 0.76 | KCNQ3 (0.47) | KMO | |
| SCHEMBL20703194 | 0.75 | KMO (0.55) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464248-B1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-22 | — | — | US | disclosed |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| EP-3464248-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017202816-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | AHR, HRH2, HRH4 | KMO 86/4885PTPN1 2253/4885GSK3B 2955/4885 |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | AHR, HRH2, HRH4 | KMO 86/4885PTPN1 2253/4885GSK3B 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.